{"entity":{"id":"origimed","kind":"company","name":"OrigiMed","aka":[],"tldr":"A Shanghai cancer genomics company whose OriMIRACLE S blood test tracks a tumour's shared mutations to look for leftover cancer.","summary":"OrigiMed is a Shanghai genomics company. Its employees co-authored the development of OriMIRACLE S, a tumour-informed residual disease test using clonal variants chosen by its OriSelector algorithm (Cancer Medicine 2023), and the whole-exome sequencing behind a 2024 osteosarcoma ctDNA study at Sun Yat-sen University (eClinicalMedicine 2024).","asOf":"2026-11-04","links":[{"label":"Qi et al., OriMIRACLE S (Cancer Medicine 2023)","url":"https://doi.org/10.1002/cam4.6286"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["mrd-testing","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-qi-orimiracle-gastrointestinal-cancer-med-2023"],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai","country":"CN","companyType":"diagnostics","investors":[],"funding":[]},"route":"/companies/origimed/","neighbours":{"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"paper":[{"id":"paper-qi-orimiracle-gastrointestinal-cancer-med-2023","kind":"paper","name":"Monitoring of gastrointestinal carcinoma via molecular residual disease with circulating tumor DNA using a tumor-informed assay","route":"/key-papers/paper-qi-orimiracle-gastrointestinal-cancer-med-2023/"},{"id":"paper-fu-osteosarcoma-ctdna-eclinicalmedicine-2024","kind":"paper","name":"Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma","route":"/key-papers/paper-fu-osteosarcoma-ctdna-eclinicalmedicine-2024/"}],"drug":[{"id":"orimiracle-s","kind":"drug","name":"OriMIRACLE S","route":"/drugs/orimiracle-s/"}]}}